University College London Hospitals NHS Foundation Trust

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Retrieved on: 
Monday, January 24, 2022
Research, PTSD, SEDAR, FSE, Technology, Patient, News, Legislation, LinkedIn, Biotechnology, Hope, Canadian Armed Forces, COVID-19, Organization, Post-traumatic stress disorder, Growth, Combat Stress (charitable organisation), Addiction, GLOBE, Mental health, University College London Hospitals NHS Foundation Trust, Psychotherapy, Instagram, Veteran, OTC, King's College London, Anxiety, Phrase, Company, Drug development, Digital technology, Depression, Therapy, Trauma, Sale, Twitter, Principal, NEO, United Kingdom, Director, Partnership, Board, Woman, Pharmaceutical industry

Combat Stress is the leading charity aiding veterans mental health in the United Kingdom, providing treatment and support to former servicemen and women for over a century.

Key Points: 
  • Combat Stress is the leading charity aiding veterans mental health in the United Kingdom, providing treatment and support to former servicemen and women for over a century.
  • I am truly excited to be leading this study at Combat Stress, stated Professor Murphy.
  • We know that the gold standard treatments for PTSD, provided by Combat Stress and other organizations, work for most veterans.
  • Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders.

DGAP-News: Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

Retrieved on: 
Thursday, January 13, 2022
Patient, Technology, B cell, The Company, Degenerative disease, Clinical trial, Catholic higher education, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Population, CEO, Horizon, University College London Hospitals NHS Foundation Trust, Department, IND, Time, Innovative Medicines Initiative, Diabetes, Company, TGA, Royal commission, CD4, Food, Granzyme, IMPACT, Peptide, Wallonia, European Commission, FDA, Investigational New Drug, Action, Faculty of Theology, Catholic University of Leuven, Type 1 diabetes, Pharmaceutical industry, Vaccine, T1D

In an exploratory analysis conducted by Professor Tim Tree, Ph.D, Department of Immunobiology, King's College London, blood samples from 17 patients were analyzed.

Key Points: 
  • In an exploratory analysis conducted by Professor Tim Tree, Ph.D, Department of Immunobiology, King's College London, blood samples from 17 patients were analyzed.
  • The U.S. FDA accepted Imcyse's IND application for the Phase 2 IMPACT Trial.
  • The Phase 2 IMPACT clinical trial is a multicenter, randomized, double-blind, placebo-controlled, dose comparison study in patients with recent onset T1D.
  • Beyond type 1 diabetes, Imcyse is developing a pipeline of ImotopesTM for the treatment of several autoimmune diseases.

Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells

Retrieved on: 
Thursday, December 2, 2021
GMP, Patient, CAR, Trade, University College London Hospitals NHS Foundation Trust, Guy's Hospital, Company, Toxicity, King's College London, Therapy, NKG2D, Research, CHF, CORE, Hospital, Series, Kings, Guy, Fine chemical, Pharmaceutical industry, Vaccine, Medical imaging

Leucid is, in turn, one of Lonza's preferred collaborators on the Cocoon Platform, and both companies will work together to optimise and streamline the manufacturing process for Leucid's CAR-T therapies.

Key Points: 
  • Leucid is, in turn, one of Lonza's preferred collaborators on the Cocoon Platform, and both companies will work together to optimise and streamline the manufacturing process for Leucid's CAR-T therapies.
  • As a preferred collaborator, Leucid will have early access to new Cocoon Platform technologies.
  • Artin Moussavi, Chief Executive Officer of Leucid Bio, said: "Following on from our successful Series A financing, we are delighted to be working with Lonza and its Cocoon Platform.
  • John Maher, Chief Scientific Officer of Leucid Bio, added: "This is a fantastic opportunity to collaborate with Lonza, enabling us to develop a state-of-the-art scalable manufacturing process.

Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells

Retrieved on: 
Thursday, December 2, 2021
GMP, Patient, CAR, Trade, Ovarian cancer, University College London Hospitals NHS Foundation Trust, Guy's Hospital, Company, Toxicity, Platinum, King's College London, Therapy, NKG2D, Research, CHF, CORE, Hospital, Series, Kings, Guy, Fine chemical, Pharmaceutical industry, Vaccine, Medical imaging

LONDON, Dec. 2, 2021 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces that it has entered a strategic collaboration with Lonza to utilize Lonza's Cocoon® Platform for the Company's forthcoming Phase I clinical trial, through to commercial manufacturing.

Key Points: 
  • Leucid is, in turn, one of Lonza's preferred collaborators on the Cocoon Platform, and both companies will work together to optimise and streamline the manufacturing process for Leucid's CAR-T therapies.
  • As a preferred collaborator, Leucid will have early access to new Cocoon Platform technologies.
  • Artin Moussavi, Chief Executive Officer of Leucid Bio, said: "Following on from our successful Series A financing, we are delighted to be working with Lonza and its Cocoon Platform.
  • John Maher, Chief Scientific Officer of Leucid Bio, added: "This is a fantastic opportunity to collaborate with Lonza, enabling us to develop a state-of-the-art scalable manufacturing process.

ZOE Study Reveals When You Go to Sleep is More Important For Your Health Than How Long You Sleep...It's Time to Go to Bed Earlier

Retrieved on: 
Wednesday, December 1, 2021
People, King's College, Lists of diseases, Lund University, COVID Symptom Study, Mental health, Protein, Fats, Candy, Time, Technology, University College London Hospitals NHS Foundation Trust, Diabetes, Rising Star, Eating, Bacteria, Attention, Hypertension, Health, Sleep, Diet, Carbohydrate, Prevalence, Snack, Blood, King's College London, Breakfast, Education, Metabolism, Your Body, Program, Department, COVID-19, Data science, Nutritional science, Machine learning, Research, Risk, Obesity, Fruit, Deloitte, Degenerative disease, Somnolence, Science, Food, Multimedia, Meal, Cardiovascular disease, Life, Vegetable, Fatigue, Energy, Pharmaceutical industry, Convenience food, Dietary supplement, Management

ZOE PREDICT is the world's largest study to gather in-depth, detailed data on sleep and nutrition.

Key Points: 
  • ZOE PREDICT is the world's largest study to gather in-depth, detailed data on sleep and nutrition.
  • This particular study on sleep is the largest to use objective measures of sleep, continuous glucose monitoring and standardized metabolic challenge tests.
  • Having an irregular weekly sleep pattern was associated with poor blood sugar control, potentially leading to short and long-term health challenges.
  • This study's findings may inform lifestyle strategies to improve postprandial blood glucose levels, focusing on earlier bedtime routines and maximizing high-quality uninterrupted sleep.

AI gut-imaging software takes on the US with FDA clearance and national hospital partnership

Retrieved on: 
Tuesday, November 23, 2021
Patient, Degenerative disease, Frimley Park Hospital, Irritable bowel syndrome, Movement, Radiological Society of North America, Magnetic resonance imaging, Technology, Crohn's disease, Nausea, AI, University College London Hospitals NHS Foundation Trust, RSNA, Comment, Hospital, NHS foundation trust, Partnership, European Society of Neurogastroenterology and Motility, Disease, King's College London, Federal Food, Drug, and Cosmetic Act, Liver, Abdominal pain, Physician, Radiology, Research, Pancreas, Decision-making, UCL, Frimley Health NHS Foundation Trust, Cost, University College London, MRI, HIV disease progression rates, Constipation, FDA, Great Ormond Street Hospital, Belle Taylor, Immunotherapy, Multimedia, Drug development, IBS, Quality of life, Medical device, Medical imaging, Animal

The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US.

Key Points: 
  • The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US.
  • Supporting the move into the US healthcare market, the company has also announced a new partnership with AI patient-care software provider Nuance.
  • With FDA clearance, our first product GIQuant can be used in combination with routine MRI to easily evaluate gastrointestinal function.
  • Peter Ellis, Chairman of Motilent says: "FDA clearance is an important step for Motilent as we move to the US market.

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Retrieved on: 
Wednesday, October 27, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Research, Polysomnography, Electroencephalography, III, SZ, Lists of diseases, Magnetic resonance, Memory, Drug discovery, Mental disorder, Sodium- and chloride-dependent glycine transporter 1, Boehringer Ingelheim, University College London Hospitals NHS Foundation Trust, Corporate headquarters, Life, Medicine, Government budget balance, Cognition, Trial of the century, Biomarker, Work, Attention, Emotion, Schizophrenia, Psychiatry, Solution, EEG, MDD, Institute of Psychiatry, Psychology and Neuroscience, Institute, Boehringer, Central nervous system, Psychology, Department, Neuroimaging, Pharmaceutical industry

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).

Key Points: 
  • Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).
  • We are delighted to collaborate with Kings IoPPN, a leading institute for research in psychiatry, said Dr Vikas Mohan Sharma, Head of Medicine CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim.
  • This collaboration will advance our understanding to better assess cognition and those biomarkers linked to cognitive deterioration in people with major depressive disorder and schizophrenia.
  • We look forward to jointly creating opportunities to accelerate future clinical trials and the development of treatments for the many people impacted by psychiatric disorders.

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Retrieved on: 
Monday, October 25, 2021
Alternative Medicine, Mental Health, Health, Clinical Trials, Pharmaceutical, Biotechnology, Safety, Depression, Research, Volunteering, TRD, Patient, Beckley Foundation, 5-MeO-DMT, University College London Hospitals NHS Foundation Trust, Principal, Clinical trial, Trial of the century, CEO, Pharmacokinetics, Metabolism, King's College London, Institute, King, Psychology, Pharmaceutical industry

The Phase 1 study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of 5-MeO-DMT in psychedelic-nave healthy subjects.

Key Points: 
  • The Phase 1 study is designed as a double-blind, randomised, single ascending dose study to evaluate the safety and tolerability of a single intranasal dose of 5-MeO-DMT in psychedelic-nave healthy subjects.
  • This is the first clinical study to measure the pharmacokinetics and metabolism of 5-MeO-DMT delivered intranasally.
  • Blinded data from the study will be used to inform the planned Phase 2 study dose and design in H1 2022.
  • The study will enrol up to 42 volunteers to evaluate the safety, tolerability, and pharmacokinetics of single ascending intranasal doses of 5-MeO-DMT.

Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

Retrieved on: 
Monday, October 25, 2021
Respiratory disease, Research, RAS, UCLH, University College Hospital, UCL, Degenerative disease, Vaccination, LifeArc, Regeneration, Patient, II, FDA, Time-invariant system, Adult, CEO, COVID-19, University College London Hospitals NHS Foundation Trust, IPF, Therapy, Paper, Pharmaceutical industry

STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet. The paper is available online via this link.

Key Points: 
  • - Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.
  • In this 106 patient phase 2 trial, data suggest that treatment with C21 may have reduced progression to more severe respiratory disease.
  • The pivotal phase 3 trial ATTRACT-32was approved by the FDA in June 2021 based on results from the ATTRACT trial.
  • The compound is currently in a phase 2 proof-of-concept trial in IPF and in a pivotal phase 3 trial in COVID-19.

Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

Retrieved on: 
Monday, October 25, 2021
Respiratory disease, Research, RAS, UCLH, University College Hospital, UCL, Degenerative disease, Vaccination, LifeArc, Regeneration, Patient, II, FDA, Time-invariant system, Adult, CEO, COVID-19, University College London Hospitals NHS Foundation Trust, IPF, Therapy, Paper, Pharmaceutical industry

The phase 2 trial ATTRACT1was organized and conducted in the full heat of the 2020 COVID-19 outbreak.

Key Points: 
  • The phase 2 trial ATTRACT1was organized and conducted in the full heat of the 2020 COVID-19 outbreak.
  • In this 106 patient phase 2 trial, data suggest that treatment with C21 may have reduced progression to more severe respiratory disease.
  • The pivotal phase 3 trial ATTRACT-32was approved by the FDA in June 2021 based on results from the ATTRACT trial.
  • The compound is currently in a phase 2 proof-of-concept trial in IPF and in a pivotal phase 3 trial in COVID-19.